These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21994418)

  • 1. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
    Fishman MN; Thompson JA; Pennock GK; Gonzalez R; Diez LM; Daud AI; Weber JS; Huang BY; Tang S; Rhode PR; Wong HC
    Clin Cancer Res; 2011 Dec; 17(24):7765-75. PubMed ID: 21994418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting activity of a TCR/IL-2 fusion protein against established tumors.
    Wen J; Zhu X; Liu B; You L; Kong L; Lee HI; Han KP; Wong JL; Rhode PR; Wong HC
    Cancer Immunol Immunother; 2008 Dec; 57(12):1781-94. PubMed ID: 18369620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein.
    Belmont HJ; Price-Schiavi S; Liu B; Card KF; Lee HI; Han KP; Wen J; Tang S; Zhu X; Merrill J; Chavillaz PA; Wong JL; Rhode PR; Wong HC
    Clin Immunol; 2006 Oct; 121(1):29-39. PubMed ID: 16807113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
    Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity.
    Card KF; Price-Schiavi SA; Liu B; Thomson E; Nieves E; Belmont H; Builes J; Jiao JA; Hernandez J; Weidanz J; Sherman L; Francis JL; Amirkhosravi A; Wong HC
    Cancer Immunol Immunother; 2004 Apr; 53(4):345-57. PubMed ID: 14610621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
    Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
    Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
    Rahma OE; Ashtar E; Czystowska M; Szajnik ME; Wieckowski E; Bernstein S; Herrin VE; Shams MA; Steinberg SM; Merino M; Gooding W; Visus C; Deleo AB; Wolf JK; Bell JG; Berzofsky JA; Whiteside TL; Khleif SN
    Cancer Immunol Immunother; 2012 Mar; 61(3):373-84. PubMed ID: 21927947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
    Giantonio BJ; Alpaugh RK; Schultz J; McAleer C; Newton DW; Shannon B; Guedez Y; Kotb M; Vitek L; Persson R; Gunnarsson PO; Kalland T; Dohlsten M; Persson B; Weiner LM
    J Clin Oncol; 1997 May; 15(5):1994-2007. PubMed ID: 9164211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
    Steeghs N; Gomez-Roca C; Rohrberg KS; Mau-Sørensen M; Robbrecht D; Tabernero J; Ahmed S; Rodríguez-Ruiz ME; Ardeshir C; Schmid D; Sleiman N; Watson C; Piper-Lepoutre H; Dejardin D; Evers S; Boetsch C; Charo J; Teichgräber V; Melero I
    Clin Cancer Res; 2024 Jul; 30(13):2693-2701. PubMed ID: 38630781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.
    Gillessen S; Gnad-Vogt US; Gallerani E; Beck J; Sessa C; Omlin A; Mattiacci MR; Liedert B; Kramer D; Laurent J; Speiser DE; Stupp R
    Eur J Cancer; 2013 Jan; 49(1):35-44. PubMed ID: 22918078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.
    Arienti F; Sulé-Suso J; Belli F; Mascheroni L; Rivoltini L; Melani C; Maio M; Cascinelli N; Colombo MP; Parmiani G
    Hum Gene Ther; 1996 Oct; 7(16):1955-63. PubMed ID: 8930655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
    King DM; Albertini MR; Schalch H; Hank JA; Gan J; Surfus J; Mahvi D; Schiller JH; Warner T; Kim K; Eickhoff J; Kendra K; Reisfeld R; Gillies SD; Sondel P
    J Clin Oncol; 2004 Nov; 22(22):4463-73. PubMed ID: 15483010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
    Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.